Posted by Michael Wonder on 28 Oct 2020
Forxiga cardiovascular outcomes benefit approved in China
28 October 2020 - Update to approval includes DECLARE-TIMI 58 Phase 3 trial that reduced the risk of composite of hospitalisation for heart failure or cardiovascular death in type 2 diabetes mellitus
China’s National Medical Products Administration has updated the label for AstraZeneca’s Forxiga (dapagliflozin) to include data from the DECLARE-TIMI 58 Phase III trial.
